STOCK TITAN

Nanobiotix reports 50.9M shares, 54.7M votes

(Neutral)
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Nanobiotix S.A. (NBTX) reported its share capital and voting rights position as of August 31, 2026. The company had 50,941,528 shares outstanding, corresponding to 54,701,246 theoretical voting rights and 54,679,128 exercisable voting rights, in line with French disclosure requirements for tracking shareholder threshold crossings.

Positive

  • None.

Negative

  • None.
Shares outstanding 50,941,528 shares As of August 31, 2026
Total theoretical voting rights 54,701,246 voting rights As of August 31, 2026; basis for calculating threshold crossings
Total exercisable voting rights 54,679,128 voting rights As of August 31, 2026; excludes suspended voting rights
Patent families More than 30 patent families Associated with three nanotechnology platforms
Nanotechnology platforms 3 platforms Applications in oncology, bioavailability and biodistribution, and CNS disorders
theoretical voting rights regulatory
"The total number of theoretical (or “gross”) voting rights is used"
Theoretical voting rights are the share of control an investor would have if all possible sources of additional shares—such as stock options, warrants and convertible bonds—were turned into ordinary shares. Investors care because this “what-if” number shows potential dilution of current owners and the maximum voting power others could gain, helping assess control risk and how future actions might change company decisions, like a snapshot of ownership if every coupon were cashed in.
exercisable voting rights regulatory
"The total number of exercisable at a shareholders’ meeting (or “net”) voting rights"
Exercisable voting rights are the actual, usable votes attached to a security or position that allow the holder to influence company decisions at shareholder meetings—for example electing the board or approving mergers. They matter to investors because the number of votes someone can cast determines who controls the company and its strategy, similar to having usable tickets at a town meeting rather than placeholders, and can affect share value, takeover risk and how much influence minority holders have.
threshold crossings regulatory
"used as the basis for calculating threshold crossings"
treasury shares financial
"without taking into account shares for which voting rights have been suspended as shares held in treasury"
Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.
French Commercial Code regulatory
"In accordance with articles L.233-8 II of the French Commercial Code"
The French Commercial Code is the national rulebook that sets the legal framework for business activity in France, covering company formation and governance, commercial contracts, trade practices, bankruptcy procedures and the role of commercial courts. For investors, it matters because these rules determine how companies are structured, how contracts and disputes are handled, and how creditor and shareholder rights are protected — like an operating manual that shapes business risk and legal recourse.
Autorité des Marchés Financiers regulatory
"223-16 of the General Regulation of the French Financial Markets Authority"
Autorité des marchés financiers is the French-language name for an independent government agency that supervises and enforces rules for securities markets, financial firms, and investor protection. It matters to investors because it requires companies to publish accurate information, polices fraud and insider trading, and can suspend trading or impose penalties—acting like a referee and safety inspector to help markets stay fair and reliable and to give investors confidence and recourse.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares of Nanobiotix S.A. (NBTX) were outstanding on August 31, 2026?

On August 31, 2026, Nanobiotix S.A. had 50,941,528 shares outstanding, as disclosed in its voting rights and share capital update filed in accordance with French regulatory requirements.

What are the total theoretical voting rights of NBTX as of August 31, 2026?

As of August 31, 2026, Nanobiotix S.A. reported 54,701,246 theoretical voting rights, which include all shares to which voting rights are attached, even those for which voting rights have been suspended.

What are the total exercisable voting rights of Nanobiotix S.A. (NBTX) as of August 31, 2026?

Nanobiotix S.A. reported 54,679,128 exercisable voting rights as of August 31, 2026. These exclude shares with suspended voting rights, such as treasury shares, and are used for shareholders’ meeting participation.

Why does Nanobiotix S.A. report both theoretical and exercisable voting rights?

Nanobiotix S.A. reports theoretical and exercisable voting rights to comply with French rules for tracking shareholder threshold crossings and to ensure the public is properly informed about voting power at shareholders’ meetings.

On which markets are Nanobiotix S.A. (NBTX) shares listed?

Nanobiotix S.A. is listed on Euronext Paris (Compartment B) and on the Nasdaq Global Select Market in New York City, under the ticker symbol NBTX.

What is the ISIN code for Nanobiotix S.A. (NBTX) shares?

The ISIN code for Nanobiotix S.A. shares is FR0011341205, as stated in the company’s voting rights and share capital disclosure dated September 22, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026

Commission File Number: 001-39777

Nanobiotix S.A.
(Translation of registrant's name into English)

60 Rue de Wattignies 75012 Paris, France
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

 

 


On September 22, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated September 22, 2026


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Nanobiotix S.A.    
  (Registrant)
   
  
Date: September 22, 2026     /s/ Bart Van Rhijn    
  Bart Van Rhijn
  Chief Financial Officer
  

EXHIBIT 99.1

Voting Rights and Shares Capital of the Company

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

PARIS, Sept. 22, 2026 (GLOBE NEWSWIRE) --
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

Date
Number of Shares
Outstanding
Total number of voting rights
Total voting rights,
theoretical1
Total voting rights,
exercisable2
August 31, 202650,941,52854,701,24654,679,128
    

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has a subsidiary in Cambridge, Massachusetts (United States).

Nanobiotix is the owner of more than 30 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

_________________________________

1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

2 The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.

Contacts

Nanobiotix
Communications Department
Brandon Owens
VP, Communications
+1 (617) 852-4835
contact@nanobiotix.com
Investor Relations Department
Joanne Choi
VP, Investor Relations (US)
+1 (713) 609-3150

Ricky Bhajun
Director, Investor Relations (EU)

investors@nanobiotix.com
Media Relations
France – HARDY
Caroline Hardy
+33 06 70 33 49 50
carolinehardy@outlook.fr
Global – uncapped
Becky Lauer
+1 (646) 286-0057
uncappednanobiotix@uncappedcommunications.com
  

Attachment

  • 2026-09-22 -- NBTX -- Voting Rights & Shares Capital -- FINAL (https://ml.globenewswire.com/Resource/Download/8ed40fd8-0e04-41d6-8af8-b7aed3ebb758)

Filing Exhibits & Attachments

1 document

Keep reading